Shares in Impax Laboratories (NSDQ:IPXL) rose earlier this week even though the pharmaceutical company missed expectations on Wall Street with its Q1 results.
The Hayward, Calif.-based company posted profits of $7.7 million on sales of $184.4 million for the 3 months ended March 31, for bottom-line loss of -75% on sales loss of -18.2% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Impax shares climb despite Q1 miss appeared first on MassDevice.